For better or worse the CEO and management have d

For better or worse the CEO and management have disclosed the internal control weakness that are now being addressed. I give both sides of the coin good and bad. Accounting teaches us if in doubt disclose it and never be misleading. Our CEO IMO shares that policy in the company 10Q disclosures!
Where will our market share come from once FDA grants approval?

"Our HemoStyp material is currently cut to several sizes and configuration and marketed as HemoStyp Gauze. Our potential customer base includes, without limitation, the following:"
"The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy."
Hospitals and Surgery Centers for all Internal Surgical usage (in the event we obtain FDA Class III approval)
Hospitals, Clinics and Physicians for external trauma
EMS, Fire Departments and other First Responders
Military Medical Care Providers
Hemodialysis centers
Nursing Homes and Assisted Living Facilities
Dental and Oral & Maxillofacial Surgery Offices
Veterinary hospitals
$5-$10++